EU approves GSK's once-weekly diabetes drug
March 26 (Reuters) - GlaxoSmithKline Plc said on Wednesday that it had received European marketing approval for its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan.
The drug received a positive recommendation from the European Medicines Agency (EMA) in January.
GSK said it expects to launch albiglutide in several countries in Europe in the third to fourth quarter this year.
Albiglutide is currently under review by the US Food and Drug Administration (FDA), which is expected to give its opinion on the drug by April 15.
The EMA authorisation of albiglutide was based on the results of the Harmony programme comprising eight late stage studies, the company said.
The Harmony programme involved over 5,000 patients and evaluated albiglutide against commonly-used classes of type 2 diabetes treatment, including insulin, in patients at different stages of the disease, as well as those with renal impairment.
Shares in GSK were trading up 0.2 percent at 1625.8 pence per share at 1336 GMT on the London Stock Exchange. (Reporting by Roshni Menon in Bangalore; Editing by Mathew Veedon)
- Police seek motive in fatal Washington state school shooting
- Wall St. finally turning on Amazon as Bezos magic fades
- Two deputies killed, two others hurt in California shooting spree
- Easter Island's ancient inhabitants weren't so lonely after all
- Two killed, four wounded in Washington state school shooting